Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR 1,159.90
+17.00 (1.49%)
Jul 10, 2026, 3:29 PM IST
Alivus Life Sciences Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Alivus Life Sciences stock has a consensus rating of "Strong Buy" and an average price target of ₹1,245. The average 1-year stock price forecast is 7.34% higher than the current stock price, while the lowest is ₹1,190 (+2.60%) and the highest is ₹1,315 (+13.37%).
Price Target: ₹1,245 (+7.34%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alivus Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
28.09B
from 25.52B
Increased by 10.07%
Revenue Next Year
31.26B
from 28.09B
Increased by 11.30%
EPS This Year
51.77
from 47.56
Increased by 8.84%
EPS Next Year
58.00
from 51.77
Increased by 12.04%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 28.2B | ||
| Avg | 28.1B | ||
| Low | 27.9B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 10.5% | ||
| Avg | 10.1% | ||
| Low | 9.5% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 52.70 | ||
| Avg | 51.77 | ||
| Low | 51.00 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 10.8% | ||
| Avg | 8.8% | ||
| Low | 7.2% |